India s Covaxin effectively neutralises Delta variant of Covid: US National Institute of Health
A health worker displays the empty vials of COVAXIN vaccine for COVID-19 (AP Photo)
AKIPRESS.COM - India’s Coronavirus vaccine Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research, effectively neutralises both Alpha and Delta variants of coronavirus, the U.S National Institute of Health (NIH) has said, The Indian Express reported.
The NIH said results of two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the UK and India, respectively.
Johns Hopkins-supported App Will Guide Covid Patients in India indiawest.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiawest.com Daily Mail and Mail on Sunday newspapers.
India s Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research, effectively neutralises both Alpha and Delta variants of coronavirus, the US National Institute of Health has said. The NIH said results of two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the UK and India, respectively. The top American health research institute, which has a history of strong scientific collaboration with India, also said that an adjuvant developed with funding from it has contributed to the success of the highly efficacious Covaxin, which has been administered to roughly 25 million people till date in India and elsewhere.
Covaxin has been administered to roughly 25 million people till date in India and elsewhere. (File)
Washington:
India s Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research, effectively neutralises both Alpha and Delta variants of coronavirus, the US National Institute of Health has said.
The NIH said results of two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the UK and India, respectively.
The top American health research institute, which has a history of strong scientific collaboration with India, also said that an adjuvant developed with funding from it has contributed to the success of the highly efficacious Covaxin, which has been administered to roughly 25 million people till date in India and elsewhere.
Highlights
It quoted the results of two studies.
New Delhi: The National Institutes of Health (NIH), a part of the US Department of Health and Human Services, on Tuesday (June 29, 2021) said that Covaxin effectively neutralizes Alpha and Delta variants of COVID-19.
It quoted two studies and stated that they have found that the Covaxin coronavirus vaccine generates antibodies that neutralize the Alpha and Delta variants of COVID-19, first identified in the United Kingdom and India, respectively. Results from two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralize the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the United Kingdom and India, respectively, the NIH said.